J
Jean-Daniel Lalau
Researcher at University of Picardie Jules Verne
Publications - 66
Citations - 1547
Jean-Daniel Lalau is an academic researcher from University of Picardie Jules Verne. The author has contributed to research in topics: Metformin & Diabetes mellitus. The author has an hindex of 20, co-authored 59 publications receiving 1182 citations.
Papers
More filters
Journal ArticleDOI
Metformin and other antidiabetic agents in renal failure patients
TL;DR: This review considers oral antidiabetic therapy in kidney transplant patients and the potential benefits and risks of antidi diabetic agents other than metformin in patients with chronic kidney disease (CKD), and tries to solve a paradox: met formin should be prescribed more widely because of its beneficial effects, but also less widelyBecause of the increasing prevalence of contraindications to metformIn.
Journal ArticleDOI
Therapeutic Concentrations of Metformin: A Systematic Review
TL;DR: Although metformin has been available for over 50 years and it is the key medication in first-line treatment of type 2 diabetes mellitus, major methodological and/or conceptual errors have confounded the literature on its therapeutic concentrations.
Journal ArticleDOI
Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4
Jean-Daniel Lalau,Farshad Kajbaf,Youssef Bennis,Anne-Sophie Hurtel-Lemaire,Frans M. Belpaire,Marc E. De Broe +5 more
TL;DR: Provided that the dose is adjusted for renal function, metformin treatment appears to be safe and still pharmacologically efficacious in moderate-to-severe CKD.
Journal ArticleDOI
The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis
Farshad Kajbaf,Jean-Daniel Lalau +1 more
TL;DR: In 56 cases of severe metformin-associated lactic acidosis, blood pH and lactate did not have prognostic value, and one can reasonably rule out the extent of met formin accumulation as a prognostic factor.
Journal ArticleDOI
Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects.
TL;DR: Having demonstrated the rapid elimination of metformin from plasma and its slow disappearance from erythrocytes, the present results should contribute to adjustment of met formin dosage to renal function, assessment of drug compliance, and retrospective analysis of the link between meetformin and development of lactic acidosis.